 | Adenosine Receptors in Neurodegenerative Diseases Adenosine Receptors in Neurodegenerative Diseases covers the role of adenosine receptors in brain function, also focusing on related methodologies and perspectives in therapeutics. The book provides an up-to-date overview by the best specialists in the field, helping readers consider the importance of adenosine and expand the global impact and visibility of adenosine research in the CNS field. Chapters include adenosine biology and signaling, gene regulation, control of motor function, and novel adenosine-based therapies in the CNS. It is an ideal resource for researchers, advanced graduate students, clinicians, and industry scientists working in the fields of clinical neuroscience and molecular and cellular neuroscience. Dr. David Blum is Research Director at Inserm in the "Alzheimer & Tauopathies" laboratory, a founder unit of the Jean-Pierre Aubert Research Centre (UMR-S 1172; Lille, France). His group is particularly focused on how environmental factors affect brain disorders with a particular interest towards caffeine. His current topic in this field relates to the impact of adenosine receptor modulation in neurological and neurodegenerative disorders as well as to the better understanding of molecular effects of caffeine into the brain. David has also a strong interest to translate his findings towards clinical studies, epidemiological and genetics. David graduated at Strasbourg University, France; obtained his PhD in Neurosciences at Grenoble University, France in 1999; and developed post-doctoral research experience at ULB, Brussels, Belgium. He has been recruited as senior researcher at Inserm in 2006. His main contributions includes the description of the complex role of adenosine receptors in Huntington's disease and the first demonstration of regulatory role of A2A receptor contribution in Tauopathies (with Dr. Lopes). David authors more that 90 papers with more that 2500 citations, including top Neuroscience Journals as Lancet Neurology, Molecular Psychiatry, Journal of Neuroscience, Neurobiology of Aging or Human Molecular Genetics. David serves in several editorial boards as associate editors and as expert for most Neuroscience journals and fundings agencies in his field. Lu#65533;sa V. Lopes is a Group leader@iMM Lisboa, Portugal. Her current work focuses on understanding the mechanisms inducing the "early-aging" of the cognitive function. The team has extensively provided evidence for an important contribution of adenosine receptors in pathophysiological context, and their impact in noxious brain conditions such as stress, aging and neurodegeneration, being awarded by FEBS, FENS and EMBO. Luisa graduated in Lisbon in 1998 in Biochemistry and then pursued a PhD in Neurosciences being trained in the University of Cambridge, UK and at the Karolisnka Institute, Sweden. She acquired postdoctoral experience in a company setting (Nestl#65533; Research Center; Switzerland) studying brain-gut interactions with particular focus on early-life stress. Luisa established her own research group in 2013 as recipient of an Investigator FCT position. Her contribution includes providing the crucial first evidence of a possible glucocorticoid-adenosine link in Alzheimer's disease (with D. Blum) following previous groundwork suggesting circadian disorders as a trigger for accelerated cognitive loss. She has authored more than 40 papers in international peer-reviewed journals with over 1000 citations. These include top journals in the field of neuroscience, such as Molecular Psychiatry, Neurobiology of Ageing, Journal of Neuroscience, as a senior author; including an award publication in TINS. Luisa has also served as a Board Member of Portuguese Society for Neuroscience and got an award from DANA Alliance for her work in raising public awareness for brain research. |
